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We present a case of a 39-year-old woman with polycystic
kidney disease who started peritoneal dialysis in 2000. Four
years later, the patient received a cadaver donor transplant
from a 52-year-old woman. Surgery was performed without
technical difﬁculties and good initial graft perfusion was
observed. An immunosuppressive regimen consisting of
tacrolimus, mycophenolate mofetil and steroids was initiated.
The post-operative course showed persistent anuria
with dependency on dialysis every 48 h. Isotopic renogram
demonstrated a vascular pattern with an almost ﬂat excretion
curve. Renal biopsy showed broad ischaemic necrosis of
the tissue sample.
Detailed screening for thrombosis risk factors revealed
increased prothrombin immunoreactivity and molecular
genetic analysis identiﬁed a heterozygous point mutation
at position 20210 of the prothrombin gene.
Recently, a clinical study reported the potential for
inherited hypercoagulability due to the V Leiden factor
or prothrombin G20210A, to predispose to acute graft
thrombosis [1].
The G20210A prothrombin mutation occurs in 1–2% of
the population and represents a frequent cause of inherited
thrombophilia.
Our patient developed RCN in the early post-transplant
period. Organ transport, storage and transplantation
problems and haemodynamic instability or rejection in
the early post-transplant period were ruled out. Only the
G20210A mutation of the prothrombin gene was found.
The G20210A prothrombin mutation is a risk factor for
graft loss and is linked to a high frequency of acute vascular
rejection due to the broad antigen exposure triggered
by vascular wall injury and induced by the prothrombotic
state [1,2].
The ﬁrst case series of patients heterozygous for the
G20210A prothrombin mutation and unsuccessful kidney
transplantation was published in 1999 and included three
renal transplant recipients who experienced graft loss due
to thrombosis in the peri-operative period [3]. The G20210A
mutation is also associated with a 2.95-fold increased risk
for allograft loss, an observation that provides the basis
for screening recipients before renal transplantation [4].
In contrast, screening of 562 transplant recipients found
a prevalence of 2% and no signiﬁcant differences were
reported in the 30 day and 1 year graft survival rates among
patients with or without the G20210A mutation [5].
It seems reasonable to believe that endothelial injury
and ischaemic-reperfusion syndrome were related to trans-
plantation in a woman with no previous history of
thrombophilia, but with a heterozygous point mutation at
position 20210 of the prothrombin gene, could trigger RCN.
New research is required to elucidate the role of this
mutation in the course of kidney transplantation.
Conﬂict of interest statement. None declared.
1Hospital Clinic
Department of Nephrology
and Renal Transplantation
2Hospital Clinic
Department of Haemotherapy
and Haemostasis
Barcelona
Spain
Email: 36008lqp@comb.es
Luis F. Quintana1
Federic Cofan1
Juan C. Reverte´2
Federic Oppenheimer1
Josep M. Campistol1
1. Irish A. Hypercoagulability in renal transplant recipients.
Identifying patients at risk of renal allograft thrombosis and
evaluating strategies for prevention. Am J Cardiovasc Drugs
2004; 4: 139–149
2. Heidenreich S, Junker R, Wolters H et al. Outcome of kidney
transplantation in patients with inherited thrombophilia: data
of a prospective study. J Am Soc Nephrol 2003; 14: 234–239
3. Oh J, Schaefer F, Veldmann A et al. Heterozygous
prothrombin gene mutation: a new risk factor for early
renal allograft thrombosis. Transplantation 1999; 68: 575–578
4. Fischereder M, Schneeberger H, Lohse P et al. Increased
rate of renal transplant failure in patients with the G20210A
mutation of the prothrombin gene. Am J Kidney Dis 2001;
38: 1061.4
5. Pherwani AD, Winter PC, McNamee PT et al. Is screening for
factor V Leiden and prothrombin G20210A mutations in renal
transplantation worthwhile? Results of a large single-center
U.K. study. Transplantation 2003; 76: 603–605
doi:10.1093/ndt/gﬁ341
Advance Access publication 19 December 2005
A puzzling case of high serum creatinine
in a healthy woman
Sir,
A 42-year-old woman with a history of recurrent urinary
tract infection presented to the emergency room with acute
malaise and abdominal pain. On physical examination,
the patient was febrile and the right kidney was painful on
percussion. Blood tests showed moderate leukocytosis,
high C-reactive protein (>200mg/l) and a serum creatinine
and serum urea in the normal range. A dipstick analysis of
the urine revealed leukocyturia and bacteriuria and the
abdominal ultrasound showed normal kidneys. An acute
pyelonephritis was diagnosed and after a 3-day course of
intravenous antibiotics the patient was discharged afebrile
and in good condition with a prescription of levoﬂoxacin for
another 7 days.
Ten days later, the patient was seen by the general
practitioner. At that time, the patient appeared healthy with
normal body temperature and an unremarkable abdominal
examination. Surprisingly, the serum creatinine was consider-
ably elevated (400mmol/l; normal range: 45–102 mmol/l).
The blood test was repeated by a second general practitioner
and conﬁrmed the previous results. A computerized tomo-
graphy scan of the abdomen was performed and revealed
no pathological ﬁndings. Acute renal failure was suspected
and the patient was admitted to our hospital for further
examination. The physical examination was still unremark-
able (i.e. no signs of uraemia). The blood tests were repeated
and serum creatinine (82 mmol/l) and serum urea (3.3mmol/l;
normal range: 2–8mmol/l) values were in the normal range.
How can the highly pathological serum creatinine
measured by both general practitioners in this obviously
healthy woman be explained? The general practitioners
used the enzymatic method (Reﬂotron Creatinine; Roche
Diagnostics, Switzerland) for serum creatinine analysis,
whereas the Jaffe´ method was applied in our hospital.
In the enzymatic assay, the non-proteinogenic amino acid
sarcosine is formed in the course of the reaction (Table 1).
Sarcosine, an intermediary of one-carbon metabolism, is
usually undetectable in human blood and, therefore, does
not interfere with the test. To support the diagnosis of
sarcosinaemia, the patient’s serum creatinine level was
measured on a single blood sample level using both the
enzymatic and the Jaffe´ method simultaneously. The serum
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creatinine level was 403mmol/l (enzymatic method) and
79 mmol/l (Jaffe´ method), respectively. The diagnosis was
conﬁrmed in our patient by an amino acid analysis (HPLC
ion-exchange chromatography) that revealed substantial
sarcosinaemia of 460 mmol/l. The high concentration of
sarcosine interfered with the enzymatic test method used
by the practitioners.
Sarcosinaemia is caused by a deﬁciency of sarcosine
dehydrogenase [1] and was originally described in 1966
in a brother and sister with mild mental retardation [2].
Later on, newborn screening programmes revealed that
this inherited defect of amino acid metabolism occurs
in about 1:350 000 (New England) and reﬂects mainly
a benign metabolic state [3]. The gene for human sarcosine
dehydrogenase is localized on chromosome 9q34 and
genetic data are consistent with an autosomal recessive
mode of inheritance.
The Jaffe´ method is known to be rather unspeciﬁc
and to interfere with a number of compounds, but not
with sarcosine. Thus, in the presence of sarcosinaemia, the
serum creatinine concentration is more accurately determined
by the not speciﬁc Jaffe´ than by the speciﬁc enzymatic
method.
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Table 1. The Reﬂotron creatinine assay
Substrates Enzymes Products
CreatinineþH2O !
Creatinine iminohydrolase
N-MethylhydantoineþNH3
N-Methylhydantoineþ 2H2OþATP !
NMethylhydantoine amidohydrolase
N-CarbamoylsarcosineþADPþP
N-CarbamoylsarcosineþH2O !
NCarbamoylsarcosine amidohydrolase
SarcosineþCO2þNH3
SarcosineþH2OþO2 !Sarcosine oxidase GlycineþHCHOþH2O2
H2O2þ indicator !Peroxidase DyeþH2O
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